Genmab A/S (NASDAQ:GMAB) Shares Sold by Oppenheimer Asset Management Inc.

Oppenheimer Asset Management Inc. reduced its holdings in shares of Genmab A/S (NASDAQ:GMAB) by 10.8% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 207,107 shares of the company’s stock after selling 25,136 shares during the quarter. Oppenheimer Asset Management Inc.’s holdings in Genmab A/S were worth $4,322,000 at the end of the most recent quarter.

Several other large investors also recently made changes to their positions in GMAB. GAMMA Investing LLC raised its holdings in shares of Genmab A/S by 96.6% during the 4th quarter. GAMMA Investing LLC now owns 2,139 shares of the company’s stock valued at $45,000 after buying an additional 1,051 shares during the period. Cromwell Holdings LLC raised its stake in shares of Genmab A/S by 656.8% during the fourth quarter. Cromwell Holdings LLC now owns 2,876 shares of the company’s stock valued at $60,000 after purchasing an additional 2,496 shares during the period. R Squared Ltd acquired a new position in shares of Genmab A/S during the fourth quarter worth $93,000. Allspring Global Investments Holdings LLC lifted its position in shares of Genmab A/S by 43.6% during the third quarter. Allspring Global Investments Holdings LLC now owns 4,653 shares of the company’s stock worth $113,000 after purchasing an additional 1,413 shares in the last quarter. Finally, Blue Trust Inc. boosted its stake in shares of Genmab A/S by 33.4% in the fourth quarter. Blue Trust Inc. now owns 5,757 shares of the company’s stock valued at $120,000 after purchasing an additional 1,442 shares during the period. Institutional investors and hedge funds own 7.07% of the company’s stock.

Genmab A/S Trading Down 0.3 %

Shares of GMAB opened at $22.67 on Friday. Genmab A/S has a 52 week low of $18.64 and a 52 week high of $31.88. The firm has a market cap of $15.00 billion, a price-to-earnings ratio of 13.03, a PEG ratio of 2.65 and a beta of 0.96. The stock has a 50 day moving average of $20.98 and a 200-day moving average of $22.78.

Genmab A/S (NASDAQ:GMAB) last released its quarterly earnings data on Wednesday, February 12th. The company reported $0.57 EPS for the quarter, topping analysts’ consensus estimates of $0.28 by $0.29. Genmab A/S had a net margin of 36.30% and a return on equity of 16.78%. On average, sell-side analysts predict that Genmab A/S will post 1.45 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

GMAB has been the topic of several analyst reports. BMO Capital Markets reaffirmed an “outperform” rating and set a $48.00 price target (up previously from $46.00) on shares of Genmab A/S in a research note on Friday, November 8th. HC Wainwright reaffirmed a “buy” rating and set a $50.00 target price on shares of Genmab A/S in a research report on Thursday, January 23rd. Sanford C. Bernstein raised Genmab A/S from a “strong sell” rating to a “hold” rating in a report on Friday, December 20th. Leerink Partnrs upgraded Genmab A/S from a “hold” rating to a “strong-buy” rating in a report on Thursday, February 13th. Finally, BNP Paribas upgraded Genmab A/S from a “strong sell” rating to a “hold” rating in a research note on Tuesday, February 11th. Four investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $42.17.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.